Attruby
(acoramidis)ApprovedSmall molecule
Acoramidis is used to treat a heart condition where an abnormal protein builds up in the heart muscle, making it thick and stiff so the heart cannot pump blood effectively. The medication works by stabilizing the protein and preventing it from damaging the heart.[2] Attruby is currently approved and in use across 6 indications[4].[1]
Attruby is one of 98 small molecule programs targeting Transthyretin Amyloid Cardiomyopathy. It is currently in Approved.
6
Indications
11
Total Trials
7
Active Trials
97
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
13
Patents
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
96 competitors in ART
#DrugCompanyPhaseTrials
1Attruby
NNavire Pharma Inc., a BridgeBio company
Approved
Belamaf
GSKPhase 3
Venclexta
AbbViePhase 3
Rituxan
RochePhase 3
Lorelco
SanofiPhase 3
Toradol
JJavelin Pharmaceuticals
Phase 3
Treanda
AAzurity Pharmaceuticals
Phase 3
Brukinsa
BBeOne Medicines
Phase 3
Cysteine Hydrochloride
NovartisPhase 2
Noradrenaline
IInstitute of Liver and Biliary Sciences, India
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Single Dose2 trials
Transthyretin Amyloid Cardiomyopathy2 trials
3 more indications
Biomarkers1 trial
Regulatory
FDA Approval Timeline[5]
Nov 22, 2024
ATTRUBY
NDA NDA216540
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Attruby drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for acoramidis. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]